B. Riley Expects Stronger Earnings for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at B. Riley upped their Q2 2025 EPS estimates for Eton Pharmaceuticals in a research note issued on Wednesday, June 4th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of ($0.04) per share for the quarter, up from their prior estimate of ($0.06). B. Riley currently has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $0.58 EPS, FY2026 earnings at $1.13 EPS and FY2027 earnings at $1.83 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The firm had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million.

Several other research firms have also recently commented on ETON. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price (up previously from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $16.84 on Monday. The business’s 50 day simple moving average is $16.24 and its 200 day simple moving average is $14.95. Eton Pharmaceuticals has a one year low of $3.18 and a one year high of $21.48. The stock has a market capitalization of $451.62 million, a PE ratio of -76.55 and a beta of 1.28.

Institutional Trading of Eton Pharmaceuticals

Several hedge funds have recently bought and sold shares of ETON. AlphaQuest LLC acquired a new stake in Eton Pharmaceuticals in the 1st quarter valued at $53,000. Tower Research Capital LLC TRC acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at about $86,000. Quantbot Technologies LP acquired a new position in Eton Pharmaceuticals during the 1st quarter valued at about $101,000. Jefferies Financial Group Inc. acquired a new position in Eton Pharmaceuticals during the 4th quarter valued at about $133,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its stake in Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after purchasing an additional 1,634 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.